Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non–Small Cell Lung Cancer

Published:2019-10-01 Issue:10 Volume:5 Page:1481
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Kazandjian Dickran¹²,Gong Yutao¹,Keegan Patricia¹,Pazdur Richard¹,Blumenthal Gideon M.¹

Affiliation:

1. Oncology Center of Excellence, Office of Hematology and Oncology Products, US Food and Drug Administration, Silver Spring, Maryland

2. Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2738768/jamaoncology_kazandjian_2019_br_190004.pdf

Reference9 articles.

1. The time-series behavior of neutrophil-to-lymphocyte ratio is useful as a predictive marker in non-small cell lung cancer.;Kiriu;PLoS One,2018

2. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.;Suh;Cancer Immunol Immunother,2018

3. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab.;Nakaya;Int J Clin Oncol,2018

4. A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.;Zhu;Onco Targets Ther,2016

5. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials.;Maymani;Lung Cancer,2018

Cited by 164 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical multi-dimensional prognostic nomogram for predicting the efficacy of immunotherapy in NSCLC;Scientific Reports;2024-09-13

2. Integration of clinical and blood parameters in risk prognostication for patients receiving immunochemotherapy for extensive stage small cell lung cancer: real-world data from two centers;BMC Medicine;2024-09-11

3. Longitudinal Changes of CT-radiomic and Systemic Inflammatory Features Predict Survival in Advanced Non–Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors;Journal of Thoracic Imaging;2024-08-27

4. Derived Neutrophils to Lymphocyte Ratio Predicts Survival Benefit from TPF Induction Chemotherapy in Local Advanced Oral Squamous Cellular Carcinoma;Cancers;2024-07-30

5. Predictors of the immunochemotherapy effectiveness of atezolizumab in combination with etoposide and carboplatin in patients with advanced small cell lung cancer;Meditsinskiy sovet = Medical Council;2024-07-24